Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics.
October 04 2021 - 7:30AM
Business Wire
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or
the “Company”) today announced that it was awarded a small
business innovation research grant in the amount of $250,000
(“Computer-aided Design for Improved Lantibiotics” R41GM136034) for
the Company’s continued research and development of lantibiotics,
including its collaborative program with the Biomolecular Sciences
Institute at Florida International University (FIU). The grant
provides Oragenics with funding to develop novel lantibiotics for
the treatment of ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.).
The NIGMS is a branch of the National Institutes of Health (NIH)
that supports basic research that increases our understanding of
biological processes and lays the foundation for advances in
disease diagnosis, treatment, and prevention. NIGMS notes that with
the ever-increasing problem of antibiotic resistance and the
concurrent use of antibiotics in the food chain and in agriculture,
there is an urgent and unmet need for new classes of
antibiotics.
“We are pleased and honored to receive this non-dilutive funding
which supports the Company’s efforts in research and development of
lantibiotics and provides Oragenics with the opportunity to
potentially expand on the identification of compounds that may be
effective against life-threatening infections,” said Frederick W.
Telling, Ph.D., Oragenics’ Executive Chairman. Dr. Telling added,
“We believe that lantibiotics represent a large untapped pipeline
for the development of novel antibiotics. Mutacin 1140 is a
lantibiotic discovered by Oragenics, that has provided a basis for
the Company’s antibiotic research and development and engineering.
This funding will support additional molecular modeling efforts and
other activities, including in collaboration with FIU, to develop
new lantibiotic compounds.”
About Oragenics, Inc.
Oragenics, Inc. is a development-stage company dedicated to
fighting infectious diseases including coronaviruses and
multidrug-resistant organisms. Its lead product is Terra CoV-2, a
vaccine candidate to prevent COVID-19 and variants of the
SARS-CoV-2 virus. The Terra CoV-2 program leverages coronavirus
spike protein research licensed from the NIH and the National
Research Council of Canada NRC with a focus on addressing
supply-chain challenges, and offering more patient-friendly
administration, such as intranasal. Its lantibiotics program
features a novel class of antibiotics against infectious diseases
that have developed resistance to commercial antibiotics.
Forward-Looking Statements
This communication contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words "believe," "expect,"
"anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to, the following: the Company’s ability to advance the
development of Terra CoV-2 and lantibiotics under the timelines and
in accord with the milestones it projects; the Company’s ability to
obtain funding, non-dilutive or otherwise, for the development of
the vaccine product candidate, Terra CoV-2 and our lantibiotics,
whether through its own cash on hand, or another alternative
source; the regulatory application process, research and
development stages, and future clinical data and analysis relating
to Terra CoV-2 and lantibiotics, including any meetings, decisions
by regulatory authorities, such as the FDA and investigational
review boards, whether favorable or unfavorable; the potential
application of Terra CoV-2 to variants and other coronaviruses; the
Company’s ability to obtain, maintain and enforce necessary patent
and other intellectual property protection; the nature of
competition and development relating to COVID-19 immunization and
therapeutic treatments and demand for vaccines and antibiotics; the
Company’s expectations as to administration, manufacturing, storage
and distribution; other potential adverse impacts due to the global
COVID-19 pandemic, such as delays in regulatory review,
interruptions to manufacturers and supply chains, adverse impacts
on healthcare systems and disruption of the global economy; and
general economic and market conditions and risks, as well as other
uncertainties described in our filings with the U.S. Securities and
Exchange Commission. All information set forth in this press
release is as of the date hereof. You should consider these factors
in evaluating the forward-looking statements included in this press
release and not place undue reliance on such statements. We do not
assume any obligation to publicly provide revisions or updates to
any forward-looking statements, whether as a result of new
information, future developments or otherwise, should circumstances
change, except as otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211004005351/en/
Oragenics, Inc. Michael Sullivan, Chief Financial Officer
813-286-7900 msullivan@oragenics.com
or
LHA Investor Relations Kim Golodetz 212-838-3777
kgolodetz@lhai.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024